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Onchocerciasis and lymphatic filariasis are two neglected tropical
diseases that together affect ∼157 million people and inflict severe
disability. Both diseases are caused by parasitic filarial nematodeswith
elimination efforts constrained by the lack of a safe drug that can kill
the adult filaria (macrofilaricide). Previous proof-of-concept human
trials have demonstrated that depleting >90% of the essential nem-
atode endosymbiont bacterium,Wolbachia, using antibiotics, can lead
to permanent sterilization of adult female parasites and a safe macro-
filaricidal outcome. AWZ1066S is a highly specific anti-Wolbachia can-
didate selected through a lead optimization program focused on
balancing efficacy, safety and drug metabolism/pharmacokinetic
(DMPK) features of a thienopyrimidine/quinazoline scaffold derived
from phenotypic screening. AWZ1066S shows superior efficacy to
existing anti-Wolbachia therapies in validated preclinical models of
infection and has DMPK characteristics that are compatible with a
short therapeutic regimen of 7 days or less. This candidate molecule
is well-positioned for onward development and has the potential to
make a significant impact on communities affected by filariasis.
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macrofilaricide
Onchocerciasis (river blindness) and lymphatic filariasis (el-ephantiasis) continue to inflict serious public health prob-
lems throughout tropical communities, globally affecting more
than 38 million and 120 million people, respectively. These two
neglected tropical diseases are caused by the parasitic filarial
nematodes Onchocerca volvulus (onchocerciasis), Wuchereria
bancrofti, Brugia malayi, and Brugia timori (lymphatic filariasis)
(1). Global programs for control and elimination have been
developed, but existing approaches target only microfilariae and
require prolonged delivery with high treatment coverage to
break the transmission cycle of the long-lived adult worm (2, 3).
This inability of current drugs to kill adult parasites has high-
lighted the need for new macrofilaricidal drugs.
Wolbachia are essential for multiple components of filarial nematode
biology including larval growth, development, embryogenesis, and, ul-
timately, survival of many filarial nematodes, including the causative
parasites of onchocerciasis and lymphatic filariasis, making this symbi-
ont a validated chemotherapeutic target (4, 5). Although the macro-
filaricidal activity of doxycycline through depletion of Wolbachia has
been proven clinically (6–12), protracted treatment regimens (≥28 d)
and contraindications restrict its widespread implementation (13, 14).
Results
Lead Optimization Led to the Selection of AWZ1066S as a Preclinical
Candidate. To identify novel anti-Wolbachia chemotypes, we
screened 10,000 compounds selected from the BioFocus Soft-
Focus library using a phenotypic cell-based screen incorpo-
rating a Wolbachia-infected Aedes albopictus cell line [C6/36
(wAlbB)] as reported previously (15). From this screen, we
identified and confirmed 50 anti-Wolbachia active hits (0.5% hit
rate) that clustered into six unique chemotypes. Based on an
evaluation of drug-like properties and potency, we selected a
series of thienopyrimidines for medicinal chemistry optimization.
Through a highly integrated academic–industrial partnership,
multiparameter lead optimization was performed with over 300
analogs synthesized and assessed for both anti-Wolbachia activ-
ity and drug metabolism/pharmacokinetic (DMPK) properties
[partition coefficient (LogD), aqueous solubility, plasma protein
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binding, microsomal and hepatocyte stability] in vitro (16). In this
process, we transformed the thienopyrimidine core of the starting
hit molecule into quinazoline AWB158 and eventually azaquina-
zoline AWZ1066, resolving the metabolic weakness associated
with the original scaffold while improving potency. Optimization
of the 2-position of the azaquinazoline core led to AWZ1066,
which was selected as a front runner (Fig. 1A; see SI Appendix,
Fig. S1 for detailed structure–activity relationship analyses of this
series). AWZ1066 (racemic mixture) was active againstWolbachia
in a cell-based assay (17) with an EC50 of 2.6 ± 0.5 nM (Fig. 1B).
In an orthogonal secondary in vitro assay utilizing microfilariae
(mf) of the human parasite B. malayi, AWZ1066 reduced Wol-
bachia within the mf with an EC50 of 150 nM while having no
effect on the viability and motility of the mf at up to the top testing
concentration of 5 μM.
Specific structural features of AWZ1066, such as the li-
pophilic electron-withdrawing CF3 group in the 4-position
side chain, the nitrogen at the 8-position of the azaquinazo-
line core, and the methyl group in the 2-position of the
morpholinyl side chain, contribute significantly to potency in
both assays (SI Appendix, Fig. S1). Matched-pair analyses with
or without these individual structural features demonstrated a
10- to 100-fold potency loss. AWZ1066 has two enantiomers,
namely AWZ1066S and AWZ1066R, demonstrating minor
differences in anti-Wolbachia potency in vitro, with the (S)-
isomer, AWZ1066S, the more potent of the enantiomers in
both in vitro assays (EC50: cell assay: 2.5 ± 0.4 vs. 14.4 ±
3.7 nM; microfilaria assay: 121 vs. 408 nM) (Fig. 1C). The
predicted cost of goods for AWZ1066 and its enantiomers is
considered to be low based on two simple sequential amina-
tion steps from the readily available 2,4-dichloropyrido[2,3-d]
pyrimidine (SI Appendix, Fig. S1). This will support cost-efficient
large-scale synthesis.
Extensive comparative analysis of the two enantiomers led to
the selection of the (S)-enantiomer, AWZ1066S, as the pre-
clinical candidate based on superiority in terms of in vitro po-
tency, in vivo efficacy, and safety pharmacology (vide infra).
Fig. 1. Medicinal chemistry optimization to identify AWZ1066S, including in vitro potency and DMPK properties. (A) Progression of the thienopyrimidine
screening hit to the azaquinazoline candidate AWZ1066S through multiparameter optimization to improve potency and DMPK properties. (B) AWZ1066
treatment causes a dose-dependent reduction ofWolbachia fromWolbachia-infected cells. Images are visual representations of cells treated with doxycycline
(Top) and AWZ1066 (Bottom) at various concentrations. In the cell-based assay, C6/36 (wAlbB) cells are incubated with compounds and then stained with
SYTO11 stain, which stains cell nuclei (large, bright areas; arrowhead) andWolbachia (small, bright punctate staining; arrows) green. Automated capture and
imaging analysis is conducted by Operetta and Harmony software (PerkinElmer) (six fields per well, two wells per concentration), which generates “per-
centage of infected cells” values (shown in white; typical vehicle-treated cells have 70 to 80% infection, while doxycycline at maximum effect has 10 to 15%
infection) that are used to calculate the effective concentration of 50% inhibition of Wolbachia (EC50: doxycycline 20 nM; AWZ1066 2.6 nM). (C) Anti-
Wolbachia activity of AWZ1066S in the microfilaria assay (EC50 121 nM) in comparison with the (R)-isomer, AWZ1066R (EC50 408 nM). Doxycycline was used as
positive control (EC50 300 nM). Data are expressed as mean ± SD of five replicates for each concentration. (D) In vitro DMPK-related data of AWZ1066S
presented in a radar plot. Six axes represent human hepatocyte clearance (μL·min−1 1 × 106 cells−1) (H. Hep. CL), human microsome clearance (μL·min−1·mg−1)
(H. Mic. CL), LogD7.4 (LogD), aqueous solubility in pH 7.4 PBS buffer (μM) (Aq. Sol.), permeability in LLC-PK1 cell assay (1 × 106 cm/s) (LLC Papp), and human
plasma protein binding (%) (H. PPB). The light blue-shaded area indicates the desired DMPK property target ranges for oral administration.
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Pharmacokinetics, Pharmacodynamics, and Safety Profiles of
AWZ1066S Match the Anti-Wolbachia Macrofilaricide Target Candidate
Profile. A key criterion for anti-Wolbachia macrofilaricides is the
need for oral drug delivery, necessitating good aqueous solubility
and metabolic stability. AWZ1066S meets the desired physico-
chemical properties with acceptable solubility in both PBS buffer
(238 μM) and fasted state-simulated intestinal fluid (0.56 mg/mL),
moderate human plasma protein binding (91%), and ready for-
mulation as a salt (pKa 5.6) (Fig. 1D). The metabolic turnover of
AWZ1066S by both liver microsomes and hepatocytes across a
range of different species, including mouse, rat, dog, monkey, and
human, is low and negatively correlated with species body size
(SI Appendix, Table S3). High metabolic stability was also observed
in the in vivo mouse PK profile (total clearance 0.47 L·h−1·kg−1 and
T1/2 3.5 h) when dosed intravenously. The permeability of
AWZ1066S in an LLC-PK1 cell assay is good (Papp 7.4 × 10
6 cm/s)
and, despite being a mammalian P-gp transporter substrate
(P-gp–mediated efflux ratio 7.8), AWZ1066S showed good to
excellent oral bioavailability (range 54 to 91%) across a range
of dosages up to 250 mg/kg in the mouse (SI Appendix, Table S4).
AWZ1066S is a weak CYP2C9 inhibitor (IC50 9.7 μM) and a weak
CYP3A4 inducer (IC50 37 μM) but does not show any time-
dependent inhibition across five major human CYP450 isoforms
(CYP1A, CYP2C9, CYP2C19, CYP2D6, CYP3A).
One of the major limitations of doxycycline, the current “gold
standard” anti-Wolbachia macrofilaricide in the treatment of
filariasis, is its prolonged treatment period of 4 to 6 wk to deliver
a cure (6, 9, 10, 12). The community consensus is that novel
macrofilaricide treatments need to be implementable in 7 d or
less (5, 14). To assess if AWZ1066S could meet this demand,
determined as a threshold reduction of Wolbachia >90% in 7 d,
efficacy was evaluated in two independent animal models of fi-
larial infection. As an initial screen, we used the adult B. malayi
SCID mouse model (14). In this model, human bioequivalent
exposures to 100 mg/d doxycycline require 6 wk to mediate
>90% Wolbachia depletion within female B. malayi adult para-
sites, while the more potent second-generation tetracycline,
minocycline, still requires a 4-wk exposure bioequivalent to
100 mg/d dosing to mediate similar efficacy (18, 19). AWZ1066S
(100 mg/kg) reduced Wolbachia by 98% after only 7 d orally
administered treatment (compared with the vehicle group)
(Kruskal–Wallis statistic 50.7, P < 0.0001; Fig. 2A). Furthermore,
the release of mf was completely prevented in 9/10 mice treated
with AWZ1066S over the 6 wk of observation post treatment (SI
Appendix, Table S5). We further investigated the preclinical ef-
ficacy of 7-d AWZ1066S dosing in a second rodent filarial in-
fection system [Litomosoides sigmodontis gerbil model (20)].
After 7 d of twice-daily treatment of AWZ1066S at either 100 or
50 mg/kg orally,Wolbachia load was reduced by >99% compared
with control untreated animals, 18 wk post treatment (Kruskal–
Wallis statistic 43.5, P < 0.0001; Fig. 2B). In this model, mf
produced by female adult worms circulate in the blood and thus
peripheral microfilaremias can be tracked longitudinally post
treatment. After AWZ1066S treatment, the peripheral blood
microfilaremia began to decline from 6 wk post treatment. A
state of amicrofilaremia (absence of mf in the blood) was evident
from 14 wk post treatment in the 7-d AWZ1066S treatment
groups, a state that was sustained until the end of the experiment
at 18 wk post treatment. Thus, treatment with AWZ1066S for
7 d leads to sterilization and gradual depletion of mf with the as-
sumption, based on extensive clinical trial data with doxycycline,
that this will result in a “slow” killing of adult worms alongside an
improved safety profile. Based on PK/PD (pharmacodynamic)
modeling (21) of the available data, using human PK simula-
tions, we predict that >90% of a patient population will achieve a
90% or higher Wolbachia reduction [considered fully efficacious
clinically (8, 10, 22)] within 7 d using an oral dose of 10 mg/kg
body weight of AWZ1066S in humans (Fig. 2D and SI Appendix,
Table S6).
AWZ1066S was subsequently tested for safety pharmacology
characteristics. AWZ1066S showed very low cytotoxicity in mul-
tiple in vitro toxicology assays (SI Appendix, Table S7). AWZ1066S was
also tested against a panel of 25 well-characterized human protein
assays (23) (CEREP panel) in vitro to assess secondary pharma-
cology. The CEREP panel screen results indicated low pro-
miscuity across the panel (SI Appendix, Table S8). AWZ1066S was
negative in both the Ames test and the in vivo micronucleus assay
in the mouse (SI Appendix, Table S9). AWZ1066 was also eval-
uated for cardiovascular safety both in vitro (hERG and Nav1.5)
and in vivo (anesthetized and conscious rats; SI Appendix, Table
S10), demonstrating a low risk. In a preliminary 7-d dose range-
finding study in the rat (SI Appendix, Table S11), the “no observed
adverse effect level” for AWZ1066 was determined to be
>300 mg/kg.
Discussion
The antibacterial activity profile of AWZ1066S was examined
against a panel of clinically relevant bacterial strains, including
gram-positive and gram-negative species and strains with known
drug-resistance profiles. The data indicated that AWZ1066S is
highly specific for Wolbachia (SI Appendix, Table S12). This high
specificity of AWZ1066S against Wolbachia is a significant ad-
vantage, as it would predict minimal impact on the gut micro-
biota, lowering the risk of dysbiosis and the selection and
emergence of resistance following administration to patients, in
comparison with other anti-Wolbachia–based broad-spectrum
antibiotic treatments.
In addition to the ability to elicit efficacy after 7 d of treat-
ment, AWZ1066 also has a faster kill rate compared with other
known antibiotics tested against Wolbachia in vitro. In a time-kill
assay modified from the standard microfilaria assay, a panel of
anti-Wolbachia drugs (24) including moxifloxacin, rifampicin,
minocycline, doxycycline, and AWZ1066S was screened over a
range of exposure intervals (1, 2, and 6 d). The results show
AWZ1066S can achieve maximum reduction of Wolbachia just
after 1 d of drug exposure compared with the other antibiotics
tested (1 to 6 d of exposure; Fig. 3A). These results further
support the potential of AWZ1066S to deliver treatment time
frames of <7 d. Furthermore, differential time-to-kill profiles
suggest a novel mode of action for the AWZ1066S class com-
pared with antibiotics that work via inhibition of aspects of
protein synthesis. Genetic approaches to identify the molecular
target(s) of AWZ1066S have been thwarted by the intractability
of this intracellular bacterium. However, using a proteomic ap-
proach with photoreactive chemical probes, we have identified a
number of credible Wolbachia and host proteins that are being
evaluated as potential drug targets of AWZ1066S (Fig. 3 B and C
and Dataset S1).
In conclusion, starting with a hit chemotype from a modest-scale
whole-cell screen, a medicinal chemistry-led scaffold hopping and
multiparameter optimization program has delivered a first-in-class
synthetic candidate molecule, AWZ1066S, that is highly specific
againstWolbachia. Seven-day oral dosing regimens with AWZ1066S
are capable of depleting Wolbachia >90% with sustained ster-
ilization of microfilaria production in two independent filarial
infection models. This candidate selected molecule meets all
target candidate profile criteria for an anti-Wolbachia macro-
filaricidal drug, and has entered formal preclinical evaluation.
AWZ1066S has the potential to deliver a novel antifilarial therapy
that could be deployed in target populations in a sub–7-day dosing
regimen. The compound provides a unique opportunity to make a
significant contribution to communities affected by filariasis, es-
pecially if the predicted macrofilaricidal effect can be confirmed in
clinical trials.
1416 | www.pnas.org/cgi/doi/10.1073/pnas.1816585116 Hong et al.
Materials and Methods
The Chemical Characterization of AWB158, AWZ1066S and Its HCl Salt, and
Photoreactive Probes 1 and 2. Please see SI Appendix for the synthesis of
AWB158, AWZ1066S (and its HCl salt), and photoreactive probes 1 and 2.
N2-isopropyl-N4-(2-(trifluoromethyl)benzyl)quinazoline-2,4-diamine: AWB158. 1H
NMR (400 MHz, MeOD) δ 8.23 (d, J = 8.0 Hz, 1H), 7.89 to 7.81 (m, 1H), 7.78 (d,
J = 7.8 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.56 to 7.42 (m, 4H), 5.11 (s, 2H), 4.18
to 4.06 (m, 1H), 1.13 (br, 6H); HRMS (ES) C19H20N4F3 [M+H]
+ requires
361.1640, found 361.1648; purity by HPLC 97.2%, Rt 9.255 min.
(S)-2-(3-methylmorpholino)-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)pyrido[2,3-d]
pyrimidin-4-amine: AWZ1066S. 1H NMR (400 MHz, DMSO) δ 8.98 (t, J = 5.1 Hz,
1H), 8.70 (d, J = 4.4 Hz, 1H), 8.60 (d, J = 4.3 Hz, 1H), 8.50 (d, J = 8.0 Hz, 1H),
7.95 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.0, 4.6 Hz, 1H), 7.15 (dd, J = 8.0, 4.5 Hz,
1H), 4.94 (dd, J = 16.3, 4.7 Hz, 1H), 4.79 (dd, J = 16.3, 4.8 Hz, 1H), 4.45 (m,
1H), 4.21 (d, J = 13.1 Hz, 1H), 3.82 (d, J = 11.1 Hz, 1H), 3.58 (d, J = 11.3 Hz,
1H), 3.44 (d, J = 11.3 Hz, 1H), 3.32 to 3.23 (m, 1H), 2.99 (td, J = 13.2, 3.7 Hz,
1H), 0.87 (br, 3H); HRMS (ES) C19H19N6OF3 [M+H]
+ requires 405.1645, found
405.1641; purity by HPLC 97.8%, Rt 7.147 min. AWZ1066S HCl salt:
1H NMR
(400 MHz, DMSO) δ 10.49 (s, 1H), 9.24 (d, J = 7.8 Hz, 1H), 9.02 to 8.69 (m,
1H), 8.64 (d, J = 4.4 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.67 (dd, J = 7.9, 4.6 Hz,
1H), 7.52 (dd, J = 7.8, 5.6 Hz, 1H), 4.97 (dd, J = 15.9, 4.4 Hz, 1H), 4.88 (dd, J =
15.9, 3.9 Hz, 1H), 4.50 (m, 1H), 4.26 (d, J = 13.1 Hz, 1H), 3.88 (d, J = 10.1 Hz,
1H), 3.62 (t, J = 17.2 Hz, 1H), 3.55 to 3.13 (m, 4H), 0.98 (br, 3H).
2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2-yl)
piperidin-4-yl)ethyl (2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethyl)carbamate: photo-
reactive probe 1. 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J = 4.3 Hz, 1H), 8.61
(d, J = 4.4 Hz, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.44 (dd,
J = 7.9, 4.7 Hz, 1H), 6.98 (dd, J = 7.9, 4.5 Hz, 1H), 6.10 (t, J = 5.4 Hz, 1H), 5.02
(d, J = 5.6 Hz, 2H), 4.90 to 4.73 (m, 2H), 4.11 (t, J = 6.2 Hz, 2H), 3.05 (dd, J =
12.0, 5.7 Hz, 2H), 2.83 (t, J = 12.2 Hz, 2H), 2.10 to 1.88 (m, 2H), 1.80 to 1.62
(m, 7H), 1.59 to 1.47 (m, 4H), 1.10 (br, 2H); HRMS (ES) C29H33N9O2F3 [M+H]
+
requires 596.2704, found 596.2709; purity by HPLC 90.3%, Rt 8.888 min.
2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2-yl)
piperidin-4-yl)ethyl (1-oxo-1-((4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzyl)amino)
pent-4-yn-2-yl)carbamate: photoreactive probe 2. 1H NMR (400 MHz, CDCl3) δ
8.75 (d, J = 4.3 Hz, 1H), 8.61 (d, J = 4.3 Hz, 1H), 8.04 to 7.86 (m, 2H), 7.44 (dd,
J = 7.9, 4.6 Hz, 1H), 7.31 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.1 Hz, 2H), 6.99 (dd,
J = 8.0, 4.5 Hz, 1H), 6.75 (br, 1H), 6.27 (br, 1H), 5.65 (br, 1H), 5.02 (d, J = 5.4 Hz, 2H),
Fig. 2. In vivo anti-Wolbachia efficacy of AWZ1066S. (A and B) Anti-Wolbachia efficacy against female adult-stage B. malayi in SCID mice (A) or L. sigmo-
dontis in gerbils (B) after doxycycline (DOX), minocycline (MIN), or AWZ1066S oral treatments at the indicated doses. Tail and whisker plots are minimum,
25th, median, 75th, and maximum Wolbachia wsp or ftsz copy number per female worm in samples of 5 to 24 worms derived from groups of four to nine
animals from an individual experiment. Significant differences compared with vehicle/untreated are indicated ****P < 0.0001, **P < 0.01 (Kruskal–Wallis with
Dunn’s tests for intergroup Wolbachia variation). bid, twice a day. (C) Longitudinal effects on circulating L. sigmodontis microfilaremias −1 to 18 wk after
DOX or AWZ1066S oral treatments at the indicated doses in gerbils. (D) Result of PK/PD Monte Carlo prediction of clinical activity of AWZ1066S when dosed at
600 mg given predicted PK properties in humans and established in vitro PD properties against Wolbachia.
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4.91 to 4.72 (m, 2H), 4.67 to 4.44 (m, 2H), 4.41 to 4.27 (m, 1H), 4.19 to 4.06
(m, 2H), 3.64 (s, 1H), 2.94 to 2.73 (m, 3H), 2.65 (ddd, J = 17.0, 6.9, 2.6 Hz, 1H),
2.09 (t, J = 2.6 Hz, 1H), 1.78 to 1.66 (m, 2H), 1.59 to 1.41 (m, 2H), 1.14 to
0.96 (m, 2H); HRMS (ES) C36H35N10O3F6 [M+H]
+ requires 769.2792, found
769.2796; purity by HPLC 91.0%, Rt 9.561 min.
In Vitro Anti-Wolbachia Cell-Based Screening. Anti-Wolbachia activity was
assessed in the A·WOL high-content imaging assay as described previously
(17). In brief, this utilized a mosquito (A. albopictus)-derived cell line (C6/36),
stably infected with Wolbachia pipientis (wAlbB) with a readout of the
percentage of the cells infected with Wolbachia. The EC50 values reported
were the means of at least five individual experiments.
In Vitro Anti-Wolbachia B. malayi Microfilaria Assay and Time-Kill Assay. B.
malayi mf were obtained from patently infected Meriones unguiculatus
gerbils as described previously (25). A series dilution of compounds (five
concentrations) were incubated with 8,000 mf per well (five replicates) in
RPMI supplemented with 10% FBS, 1% penicillin streptomycin, and 1%
amphotericin B. After a 6-d incubation (37 °C, 5% CO2), motility was assessed
by microscopy and DNA was extracted for quantitative PCR (qPCR) analysis
to obtain ratios of Wolbachia surface protein copy number (wsp) to GST
copy number (gst), as previously described (26). Time-kill assays were com-
pleted using the same method with the exception of a wash step on the
indicated day. The drug concentration in the time-kill assay was 10 times
that of the EC50. There were five replicates per time point per drug treat-
ment. The EC50 values or Wolbachia reduction percentages reported were
from one individual experiment.
In Vitro Drug Metabolism/Pharmacokinetic Assays. The DMPK property data
described above were measured once through a high-throughput platform
provided by AstraZeneca UK. The methods of the five assays, including
LogD7.4, aqueous solubility, plasma protein binding, and microsome and
hepatocyte clearance measurements, have been reported previously
(27, 28).
In Vivo Anti-Wolbachia Pharmacodynamic Studies.
Animals. For B. malayi studies, inbred male SCID CB.17 mice and outbred M.
unguiculatus gerbil breeding pairs were purchased from Charles River,
Europe. Rodents were maintained/bred in specific pathogen-free conditions
at the University of Liverpool Biological Services Unit. All experiments were
approved by the animal welfare ethics committees of the University of Liv-
erpool and Liverpool School of Tropical Medicine. Studies were conducted in
accordance with Home Office legislation. Experiments with L. sigmodontis
were performed at the Institute for Medical Microbiology, Immunology and
Parasitology, University Hospital Bonn in accordance with European Union
animal welfare guidelines, and all protocols were approved by the Land-
esamt für Natur, Umwelt und Verbraucherschutz (AZ 84-02.04.2015.A507).
FemaleM. unguiculatus gerbils were obtained from Janvier Labs and housed
at the animal facility of the Institute for Medical Microbiology, Immunology
and Parasitology in individually ventilated cages on a 12-h light/dark cycle
with food and water ad libitum.
Filarial experimental infections. Infective-stage B. malayi L3 larvae were prop-
agated as previously described (14). Male mice 6 to 12 wk of age (n = 5 to 9)
or male gerbils (n = 6) 8 to 16 wk of age were infected with B. malayi L3 i.p.
(50 or 100× L3 mouse, 400× L3, gerbil). Mouse experimental infections
were maintained for 13 wk, while gerbil infections were maintained for a
Fig. 3. Unique mode of action of AWZ1066S was indicated by its fast kill rate and was investigated through a proteomic target identification approach using
two photoreactive chemical probes. (A) The Wolbachia depletion rates of AWZ1066S measured for three different treatment lengths (1, 2, and 6 d) in the B.
malayi microfilaria time-kill assay. Doxycycline, minocycline, moxifloxacin, and rifampicin were used as positive controls (only doxycycline for day 1). Data are
expressed as mean ± SD of five replicates for each time point. (B) Two photoreactive chemical probes used for target identification of AWZ1066S in Wol-
bachia. Structures (bifunctional, photoreactive, and clickable side chains are highlighted in red) and their anti-Wolbachia activity in the cell assay (n = 3). (C)
Fifty-three putative protein targets of photoreactive probes 1 and 2 assigned (as shown in the Venn diagram) based on statistical testing [right-sided t test,
permutation-based false discovery rate = 0.001, Artificial within groups variance (S0) = 3] of label-free quantification (LFQ) intensities measured in samples
derived from probe-treated cells and control, DMSO-treated cells (n = 3). Protein targets presented in the left-hand block are from W. pipientis and in the
right-hand block are from A. albopictus. Numbers within the heatmap legend represent Log2 LFQ t test differences. Protein ID codes above the heatmap given
in red indicate 22 proteins identified as common targets of both probes.
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maximum of 12 mo. Motile B. malayi parasites were recovered by peritoneal
lavage at necropsy and enumerated by microscopy. Motile mf from gerbil
infections were periodically isolated by i.p. catheter drain under anesthesia
with recovery as previously described (14).
For L. sigmodontis infection, 6- to 8-wk-old female gerbils were ex-
posed to Ornithonyssus bacoti mites containing infective-stage L. sigmo-
dontis L3. Treatment of microfilaremic gerbils started 13 wk following
infection. Necropsies occurred 18 wk following the start of treatment. At
necropsy, L. sigmodontis worms were isolated from the serous cavities
and quantified as previously described (29). For microfilaria counts, 10 μL
of peripheral blood was taken from the saphenous vein in biweekly in-
tervals starting at 12 wk post infection and diluted in 300 μL of Hinkel-
mann solution (0.5% eosin Y, 0.5% phenol, 0.185% formaldehyde in
aqua dest). After centrifugation at 400 × g for 5 min, the supernatant
was discarded; the pellet was resuspended in 1 mL and transferred to a
1-mL Sedgewick Rafter Counting Chamber to quantify total mf using a
microscope.
Drug dosing. Infected animals were randomly assigned to dose groups (n= 5 to
9). AWZ1066S (or it HCl salt) was dissolved in PEG300/propylene glycol/H2O
(55/25/20). Minocycline and doxycycline hyclate (Sigma-Aldrich) were dis-
solved in water. Animals were weighed, and weight-corrected volumes of
dosing solution were administered by oral gavage (mouse: 100 μL/25 g body
weight; gerbil: 2.5 mL/kg).
Molecular assays. For B. malayi infections, determination ofWolbachia single-
copywsp gene quantity was undertaken by qPCR as previously described (14,
18) whereas, for L. sigmodontis, Wolbachia was determined by FtsZ qPCR as
previously described (30). Between 5 and 20 individual worms were assayed,
derived from dose groups of three to nine animals.
Statistical analysis. Continuous variables (Wolbachia loads, adult worm
burdens, microfilaria burdens) were tested for normal distribution by
D’Agostino and Pearson omnibus normality tests pre and post Log10 trans-
formation. Variables did not satisfy the assumption of normality and were
compared by two-tailed Kruskal–Wallis tests with Dunn’s multiple tests, post
hoc. Post hoc testing scrutinized drug groups compared with vehicle or
untreated controls. Significance levels are indicated as *P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001. All statistics were undertaken using
GraphPad Prism v6 software.
PK/PD predictions of AWZ1066S activity in clinical settings. The predicted human
pharmacokinetic parameters (SI Appendix, Table S6) were used to predict
the activity of AWZ1066S when administered in humans for 1 wk using the
simulator tool in Pmetrics (31). As previously described (21), we used a PK/PD
model which links predicted human pharmacokinetic parameters with the
observed in vitro activity of the drug against intracellular Wolbachia. One
thousand subjects were simulated and the % of subjects achieving >90%
Wolbachia reduction at each week was recorded, and data are presented as
the cumulative number of patients who achieved >90% Wolbachia load
reduction.
Preliminary Target Pull-Down Using Photoreactive Probes with Wolbachia-
Infected Cells. Please see SI Appendix for experimental details of sample
preparation and pull-down for proteomics and LC-MS/MS analysis of pro-
teomic samples and data processing.
Data Availability Statement. The authors declare that the data supporting the
findings in this manuscript are available within the paper and its SI Appendix.
The raw data related to the studies described in this manuscript are available
from the corresponding authors upon reasonable request.
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